London: Monday, 29 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM)announces the following blocklisting six monthly return:
|
1. |
Name of applicant:
|
Hutchison China MediTech Limited |
|
|
2. |
Name of scheme:
|
Hutchison China MediTech Limited Share Option Scheme
|
|
|
3. |
Period of return:
|
From 29 December 2014 to 28 June 2015 |
|
|
4. |
Balance under scheme from previous return:
|
696,051 ordinary shares of US$1 each
|
|
|
5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
|
Nil |
|
|
6. |
Number of securities issued/allotted under scheme during period: |
223,288 ordinary shares of US$1 each |
|
|
7. |
Balance under scheme not yet issued/allotted at end of the period:
|
472,763 ordinary shares of US$1 each |
|
|
8. |
Number and class of securities originally listed and the date of admission:
|
2,560,606 ordinary shares of US$1 each admitted on 26 June 2007 |
|
|
9. |
Total number of securities in issue at the end of the period: |
53,299,964 ordinary shares of US$1 each |
|
|
Name of contact:
|
Christian Hogg |
||
|
Address of contact:
|
21/F., Hutchison House, 10 Harcourt Road, Hong Kong
|
||
|
Telephone number of contact:
|
+852 2121 8200 |
||
Ends
|
Chi-Med Christian Hogg, CEO |
Telephone: +852 2121 8200
|
|
Panmure Gordon (UK) Limited |
Telephone: +44 20 7886 2500 |
|
Richard Gray Andrew Potts |
|
|
Citigate Dewe Rogerson Anthony Carlisle David Dible |
Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919 |
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:1). For more information, please visit: www.chi-med.com.